Department of Oncology UNIL CHUV,
Ludwig Institute for Cancer Research Lausanne,
Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne
Alexandre Harari has not added Biography.
If you are Alexandre Harari and would like to personalize this page please email our Author Liaison for assistance.
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy.
The Journal of clinical investigation Mar, 2002 | Pubmed ID: 11877476
Transepithelial transport of HIV-1 by M cells is receptor-mediated.
Proceedings of the National Academy of Sciences of the United States of America Jul, 2002 | Pubmed ID: 12093918
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection.
Blood Aug, 2002 | Pubmed ID: 12149221
Antiviral memory T cell responses: correlation with protective immunity and implication for vaccine development.
Advances in experimental medicine and biology , 2002 | Pubmed ID: 12405200
Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections.
European journal of immunology Dec, 2002 | Pubmed ID: 12516570
Cytomegalovirus (CMV)-specific cellular immune responses.
Human immunology May, 2004 | Pubmed ID: 15172450
Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load.
European journal of immunology Dec, 2004 | Pubmed ID: 15484193
HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells.
Proceedings of the National Academy of Sciences of the United States of America May, 2005 | Pubmed ID: 15872023
Understanding what makes a good versus a bad vaccine.
European journal of immunology Sep, 2005 | Pubmed ID: 16106373
Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases.
Nature reviews. Immunology May, 2006 | Pubmed ID: 16622477
Functional signatures of protective antiviral T-cell immunity in human virus infections.
Immunological reviews Jun, 2006 | Pubmed ID: 16824132
Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure.
AIDS (London, England) Jan, 2007 | Pubmed ID: 17148964
Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization.
European journal of immunology Apr, 2007 | Pubmed ID: 17372991
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses.
The Journal of experimental medicine Jun, 2007 | Pubmed ID: 17535971
Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2007 | Pubmed ID: 17911249
HIV-1-specific immune response.
Advances in pharmacology (San Diego, Calif.) , 2008 | Pubmed ID: 18086409
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
The Journal of experimental medicine Jan, 2008 | Pubmed ID: 18195071
Distinct profiles of cytotoxic granules in memory CD8 T cells correlate with function, differentiation stage, and antigen exposure.
Journal of virology Apr, 2009 | Pubmed ID: 19176626
Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.
Journal of virology Jun, 2009 | Pubmed ID: 19321612
Role of HIV-1-specific CD4 T cells.
Current opinion in HIV and AIDS Jan, 2006 | Pubmed ID: 19372779
Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression.
Journal of virology Apr, 2010 | Pubmed ID: 20130059
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease.
Nature medicine Mar, 2011 | Pubmed ID: 21336285
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors.
PloS one Apr, 2011 | Pubmed ID: 21483676
Large TCR diversity of virus-specific CD8 T cells provides the mechanistic basis for massive TCR renewal after antigen exposure.
Journal of immunology (Baltimore, Md. : 1950) Jun, 2011 | Pubmed ID: 21555537
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.
Journal of virology Oct, 2011 | Pubmed ID: 21775454
Functional avidity: a measure to predict the efficacy of effector T cells?
Clinical & developmental immunology , 2012 | Pubmed ID: 23227083
Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease.
European journal of immunology Jun, 2013 | Pubmed ID: 23456989
CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.
PLoS pathogens Sep, 2014 | Pubmed ID: 25255144
Combined use of Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active tuberculosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Feb, 2015 | Pubmed ID: 25362202
Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.
Journal of virology Apr, 2015 | Pubmed ID: 25609807
Personalized approaches to active immunotherapy in cancer.
Biochimica et biophysica acta Jan, 2016 | Pubmed ID: 26241169
Neoantigen-based cancer immunotherapy.
Annals of translational medicine Jul, 2016 | Pubmed ID: 27563649
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Biomedicines May, 2016 | Pubmed ID: 28536377
Sensitive and frequent identification of high avidity neo-epitope specific CD8 T cells in immunotherapy-naive ovarian cancer.
Nature communications 03, 2018 | Pubmed ID: 29545564
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Science translational medicine 04, 2018 | Pubmed ID: 29643231
Computational KIR copy number discovery reveals interaction between inhibitory receptor burden and survival.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing , 2019 | Pubmed ID: 30864318
Tumor-associated factors are enriched in lymphatic exudate compared to plasma in metastatic melanoma patients.
The Journal of experimental medicine May, 2019 | Pubmed ID: 30975896
High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2019 | Pubmed ID: 31015344
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three Patients.
Frontiers in immunology , 2019 | Pubmed ID: 31440238
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8 T cells.
Journal for immunotherapy of cancer Oct, 2019 | Pubmed ID: 31601268
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.
Nature biotechnology Nov, 2019 | Pubmed ID: 31611696
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Journal of translational medicine Nov, 2019 | Pubmed ID: 31771601
Mukul Girotra*,1,2,
Anne-Christine Thierry3,
Alexandre Harari1,3,
George Coukos1,
Olaia Naveiras2,4,
Nicola Vannini*,1
1Department of Oncology UNIL CHUV, Ludwig Institute for Cancer Research Lausanne, University of Lausanne,
2Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL),
3Center of Experimental Therapeutics, Department of Oncology, Centre Hospitalier Universitaire Vaudois,
4Hematology Service, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV)
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유